AVIRAtea Pharmaceuticals, Inc.

$501M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$20M

Operating Income

-$37M

Net Income

-$31M

EPS (Diluted)

$-0.37

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$491M

Total Liabilities

$32M

Stockholders' Equity

$459M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$20M	-$18M	-10.3%
Operating Income	-$37M	-$41M	+8.8%
Net Income	-$31M	-$33M	+6.0%

AVIR Q3 2024 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena